文献速递消化系统肿瘤

初始不可切除结直肠癌肝转移的一线全身治疗:CAIRO5随机临床试验的事后分析

First-Line Systemic Treatment for Initially Unresectable Colorectal Liver Metastases: Post Hoc Analysis of the CAIRO5 Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2025-01-01

该事后分析基于CAIRO5随机3期试验,纳入530例初始不可切除的结直肠癌肝转移患者,比较FOLFOXIRI+贝伐珠单抗与FOLFOX/FOLFIRI+贝伐珠单抗(RAS/BRAFV600E突变和/或右侧肿瘤),以及FOLFOX/FOLFIRI+帕尼单抗与FOLFOX/FOLFIRI+贝伐珠单抗(RAS/BRAFV600E野生型左侧肿瘤)的长期总生存。结果显示两组比较的总生存均无显著差异,支持无论RAS/BRAFV600E状态和肿瘤部位均使用FOLFOX/FOLFIRI+贝伐珠单抗;完成局部治疗且早期复发后仍可行挽救性局部治疗的患者总生存最长;辅助化疗与更长的总生存和无复发生存相关。

要点

  • FOLFOXIRI+贝伐珠单抗与FOLFOX/FOLFIRI+贝伐珠单抗的总生存无显著差异(HR 0.90,95%CI 0.70-1.17,P=0.44)。
  • FOLFOX/FOLFIRI+帕尼单抗与FOLFOX/FOLFIRI+贝伐珠单抗的总生存无显著差异(HR 0.95,95%CI 0.68-1.32,P=0.75)。
  • 完成局部治疗且无早期复发者总生存最长(64.3个月),持续不可切除者最差(18.3个月)。

核心结论

  • 这些结果支持对初始不可切除的结直肠癌肝转移患者使用FOLFOX/FOLFIRI+贝伐珠单抗,无论RAS/BRAFV600E状态和肿瘤部位如何。
  • 完成肝脏局部治疗且早期复发时行挽救性局部治疗的患者总生存最长。
  • 辅助化疗可能可考虑用于这些患者。

研究设计与样本

  • CAIRO5是一项随机3期试验,纳入初始不可切除的结直肠癌肝转移患者,来自46家荷兰中心和1家比利时中心。
  • 研究于2014年11月至2022年1月期间入组,共530例患者(男性327例[62%],女性203例[38%];中位年龄62岁[IQR 54-69])。
  • 患者随机分为4组:RAS/BRAFV600E突变和/或右侧肿瘤患者接受FOLFOX/FOLFIRI+贝伐珠单抗(第1组,148例)或FOLFOXIRI+贝伐珠单抗(第2组,146例);RAS/BRAFV600E野生型左侧肿瘤患者接受FOLFOX/FOLFIRI+贝伐珠单抗(第3组,118例)或FOLFOX/FOLFIRI+帕尼单抗(第4组,118例)。
  • 肝脏专家小组反复评估可切除性,总生存作为次要结局分析,其他结局为事后分析。

主要发现

  • 第1组中位总生存为23.6个月(95%CI 20.1-27.5),第2组为24.1个月(95%CI 21.0-30.9)(HR 0.90,95%CI 0.70-1.17,P=0.44)。
  • 第3组中位总生存为39.9个月(95%CI 30.7-44.6),第4组为38.3个月(95%CI 35.3-51.3)(HR 0.95,95%CI 0.68-1.32,P=0.75)。
  • 完成局部治疗且无早期(≤6个月)复发者总生存最长(64.3个月,95%CI 57.6至未达到),其次为早期复发后行挽救性局部治疗者(58.9个月,95%CI 47.3至未达到),再次为早期复发后未行挽救性局部治疗者(30.5个月,95%CI 24.4-33.4)和局部治疗不完全者(28.7个月,95%CI 25.9-38.3),持续不可切除者最差(18.3个月,95%CI 15.7-20.0)。
  • 混杂因素调整后,辅助化疗与更长的总生存相关(HR 0.66,95%CI 0.44-0.98)、更长的无复发生存相关(HR 0.65,95%CI 0.48-0.88),并与更少的早期复发且未行挽救性局部治疗相关(比值比0.46,95%CI 0.25-0.85)。

关键数值与推荐

  • 对初始不可切除的结直肠癌肝转移患者,无论RAS/BRAFV600E状态和肿瘤部位如何,支持使用FOLFOX/FOLFIRI+贝伐珠单抗。
  • 辅助化疗可能可考虑用于完成肝脏局部治疗且早期复发时行挽救性局部治疗的患者。

临床怎么用

  • 根据作者结论,初始不可切除的结直肠癌肝转移患者的一线治疗可考虑FOLFOX/FOLFIRI+贝伐珠单抗,不依赖RAS/BRAFV600E状态和肿瘤部位。
  • 作者认为,完成肝脏局部治疗且早期复发时行挽救性局部治疗的患者总生存最长。
  • 作者提出,辅助化疗可能可考虑用于上述患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: In patients with colorectal cancer and unresectable liver-only metastases (CRLM), treatment with folinic acid, fluorouracil, and oxaliplatin (FOLFOX) plus irinotecan (FOLFOXIRI) and bevacizumab vs FOLFOX/folinic acid, fluorouracil, and irinotecan (FOLFIRI) plus bevacizumab increased progression-free survival, response, and R0/R1 resection/ablation rates, as well as toxic effects in RAS/BRAFV600E-variant and/or right-sided tumors. FOLFOX/FOLFIRI-panitumumab vs FOLFOX/FOLFIRI-bevacizumab increased response at the cost of more toxic effects in RAS/BRAFV600E wild-type, left-sided tumors. OBJECTIVE: To present long-term outcomes of treatment with FOLFOXIRI plus bevacizumab vs FOLFOX/FOLFIRI plus bevacizumab and FOLFOX/FOLFIRI plus panitumumab vs FOLFOX/FOLFIRI + bevacizumab. DESIGN, SETTING, AND PARTICIPANTS: The randomized phase 3 CAIRO5 trial included patients with initially unresectable CRLM in 46 Dutch centers and 1 Belgian center between November 2014 and January 2022. A liver expert panel repeatedly evaluated resectability. INTERVENTION: Patients with RAS/BRAFV600E-variant and/or right-sided tumors randomly received FOLFOX/FOLFIRI-bevacizumab (group 1) or FOLFOXIRI-bevacizumab (group 2), and those with RAS/BRAFV600E wild-type, left-sided tumors received FOLFOX/FOLFIRI-bevacizumab (group 3) or FOLFOX/FOLFIRI-panitumumab (group 4). Adjuvant chemotherapy (ACT) after complete local treatment was recommended but not standard. MAIN OUTCOMES AND MEASURES: Overall survival (OS) was analyzed as a secondary outcome. Other outcomes were post hoc analyses. RESULTS: A total of 530 patients (327 male [62%] and 203 female individuals [38%]; median age, 62 [IQR, 54-69] years) were randomized: 148 in group 1, 146 in group 2, 118 in group 3, and 118 in group 4. The median OS in group 1 was 23.6 (95% CI, 20.1-27.5) vs 24.1 (95% CI, 21.0-30.9) months in group 2 (hazard ratio [HR], 0.90; 95% CI, 0.70-1.17; P = .44), and 39.9 (95% CI, 30.7-44.6) in group 3 vs 38.3 (95% CI, 35.3-51.3) months in group 4 (HR, 0.95; 95% CI, 0.68-1.32; P = .75). OS was longest after complete local treatment without early (≤6 months) recurrence (64.3 months; 95% CI, 57.6 to not reached) and salvage local treatment options after early recurrence (58.9; 95% CI, 47.3 to not reached), followed by patients without salvage local treatment after early recurrence (30.5; 95% CI, 24.4-33.4) and with incomplete local treatment (28.7; 95% CI, 25.9-38.3), and worst in patients with continued unresectability (18.3; 95% CI, 15.7-20.0). After confounder adjustment, ACT was associated with longer OS (HR, 0.66; 95% CI, 0.44-0.98) and relapse-free survival (HR, 0.65; 95% CI, 0.48-0.88) and less early recurrence without salvage local treatment (odds ratio, 0.46; 95% CI, 0.25-0.85). CONCLUSIONS AND RELEVANCE: These results support using FOLFOX/FOLFIRI-bevacizumab for patients with initially unresectable CRLM irrespective of RAS/BRAFV600E status and tumor sidedness. Patients with complete local liver treatment with salvage local treatment in case of early recurrence had the longest OS. ACT might be considered for these patients. TRIAL REGISTRATION: ClinicalTrials.gov NCT02162563.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Bond MJG, Bolhuis K, Loosveld OJL, et al. First-Line Systemic Treatment for Initially Unresectable Colorectal Liver Metastases: Post Hoc Analysis of the CAIRO5 Randomized Clinical Trial. JAMA Oncol. 2025. PMID: 39570583. doi:10.1001/jamaoncol.2024.5174

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。